PE 22-28 is a synthetic derivative of Spadin, an endogenous peptide that specifically blocks the TREK-1 potassium channel, a recently identified target for treating depression. PE 22-28 has been shown to induce neurogenesis after just four days, substantially faster than conventional antidepressant medications, and to stimulate synaptogenesis with fewer side effects than traditional pharmacological approaches.

What is PE 22-28?

PE 22-28 is a synthetic peptide derived from Spadin, a naturally occurring endogenous peptide with antidepressant activity. Spadin was identified as a specific blocker of the TREK-1 channel, a two-pore potassium channel expressed predominantly in the prefrontal cortex and hippocampus, the brain regions most directly involved in mood regulation, memory, and learning. PE 22-28 was developed as an improved analog of Spadin, demonstrating better TREK-1 channel inhibition, greater in vivo stability, and more potent antidepressant activity. It addresses a novel neurological target distinct from conventional monoamine-focused antidepressants, and has shown the ability to promote neurogenesis (new neuron formation) significantly faster than existing pharmacological treatments.

How does PE 22-28 work?

PE 22-28 binds to and blocks the TREK-1 potassium channel, which is primarily expressed in the prefrontal cortex and hippocampus. TREK-1 is a two-pore domain potassium channel that, when overactive, is associated with depressive states, partly through its regulation of serotonin release and neuroplasticity in these mood-governing regions. By blocking TREK-1, PE 22-28 produces mind stability and mood-enhancing effects through a mechanism distinct from SSRIs and other monoamine-targeting antidepressants. Crucially, PE 22-28 has been shown to induce neurogenesis within four days, a dramatically shorter timeframe than conventional antidepressants, which typically require weeks to stimulate measurable neurogenic activity. It also stimulates synaptogenesis, supporting the formation of new synaptic connections that underlie long-term mood and cognitive recovery.

Clinically observed benefits of PE 22-28

• Helps manage depression: TREK-1 blockade produces antidepressant effects through a mechanistically novel pathway, with research demonstrating efficacy in preclinical depression models.
• Upregulates neurogenesis in a shorter duration compared to antidepressant drugs: PE 22-28 has been shown to induce neurogenesis after just four days — substantially faster than conventional antidepressant drugs.
• Stimulates synaptogenesis: Beyond new neuron formation, PE 22-28 promotes the formation of new synaptic connections, supporting the neural architecture underlying mood and cognition.
• Fewer side effects compared to antidepressant drugs: PE 22-28’s targeted TREK-1 mechanism avoids many of the systemic side effects associated with broad monoamine reuptake inhibitors.
• Increases muscle function: Research has observed improved muscle function as a secondary benefit.
• Helps with post-stroke depression (PSD): TREK-1 channel activity is relevant in post-stroke neurological recovery, and PE 22-28’s mechanism has applications in this context.
• Helps with neurodegenerative diseases: Neurogenesis and synaptogenesis benefits extend to neurodegenerative conditions where these processes are impaired.

How is PE 22-28 administered?

PE 22-28 is available in the following compounding format:

• Nasal spray — intranasal delivery for direct CNS uptake, bypassing systemic degradation and supporting delivery to the prefrontal cortex and hippocampus

Frequently asked questions about PE 22-28

Q: How quickly does PE 22-28 produce effects?

A: Research has demonstrated that PE 22-28 can induce neurogenesis after just four days, a significantly faster timeline than conventional antidepressant drugs, which typically require weeks of treatment before neurogenic effects are measurable.

Q: Is PE 22-28 a replacement for conventional antidepressants?

A: PE 22-28 addresses a novel mechanism (TREK-1 inhibition) that is distinct from SSRIs, SNRIs, and other monoamine-targeting antidepressants. Whether it is used as a standalone, adjunct, or alternative treatment should be determined by a physician based on individual clinical context.

Q: What is the TREK-1 channel and why does it matter for depression?

A: TREK-1 is a two-pore potassium channel primarily found in the prefrontal cortex and hippocampus, the brain regions that govern mood, memory, and learning. Overactivation of TREK-1 is associated with depressive states. Blocking it with PE 22-28 produces mind stability and mood-enhancing effects through a pathway independent of the serotonin or dopamine systems targeted by most existing antidepressants.

Clinical research

Research by Djillani et al. published in Frontiers in Pharmacology (2017) demonstrated that shortened Spadin analogs, including PE 22-28, display better TREK-1 inhibition, improved in vivo stability, and enhanced antidepressant activity compared to the parent molecule Spadin. Further work by Djillani et al. in Pharmacology & Therapeutics (2019) reviewed TREK-1 blockade as a strategy for fighting depression, contextualizing PE 22-28 within the broader literature on this novel antidepressant mechanism. These studies provide the foundational peer-reviewed evidence for PE 22-28’s clinical rationale.

[Related: See our full Peptide Therapy Series]

These statements have not been evaluated by the Food and Drug Administration. These compounds are not intended to diagnose, treat, cure, or prevent any disease. This content is for informational purposes only and does not constitute medical advice. Peptide therapy should only be pursued under the supervision of a licensed physician.